Cargando…
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the preferred regimen for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. However, the optimal treatment sequencing for CDK4/6i with other availabl...
Autores principales: | Zhao, Melody, Hanson, Kent A., Zhang, Yixie, Zhou, Anna, Cha-Silva, Ashley S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191980/ https://www.ncbi.nlm.nih.gov/pubmed/37074594 http://dx.doi.org/10.1007/s11523-023-00957-7 |
Ejemplares similares
-
The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022) -
Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020) -
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
por: Susanti, Ni Made Pitri, et al.
Publicado: (2021) -
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
por: Wang, Bin, et al.
Publicado: (2021) -
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)